- Home
- BPMC vs PSO Comparison
BPMC vs PSO Comparison
Compare BPMC & PSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- PSO
- Stock Information
- Founded
- BPMC 2008
- PSO 1844
- Country
- BPMC United States
- PSO United Kingdom
- Employees
- BPMC N/A
- PSO N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- PSO Books
- Sector
- BPMC Health Care
- PSO Consumer Discretionary
- Exchange
- BPMC Nasdaq
- PSO Nasdaq
- Market Cap
- BPMC 8.3B
- PSO 9.5B
- IPO Year
- BPMC 2015
- PSO 2000
- Fundamental
- Price
- BPMC N/A
- PSO $14.31
- Analyst Decision
- BPMC Buy
- PSO
- Analyst Count
- BPMC 18
- PSO 0
- Target Price
- BPMC $128.87
- PSO N/A
- AVG Volume (30 Days)
- BPMC 4.3M
- PSO 632.3K
- Earning Date
- BPMC 07-31-2025
- PSO 01-01-0001
- Dividend Yield
- BPMC N/A
- PSO 2.22%
- EPS Growth
- BPMC N/A
- PSO 20.49
- EPS
- BPMC N/A
- PSO 0.79
- Revenue
- BPMC $562,121,000.00
- PSO $4,446,837,010.00
- Revenue This Year
- BPMC $44.46
- PSO $3.66
- Revenue Next Year
- BPMC $32.78
- PSO $3.94
- P/E Ratio
- BPMC N/A
- PSO $17.04
- Revenue Growth
- BPMC 99.19
- PSO N/A
- 52 Week Low
- BPMC $73.04
- PSO $13.10
- 52 Week High
- BPMC $129.65
- PSO $17.90
- Technical
- Relative Strength Index (RSI)
- BPMC 3.63
- PSO 41.68
- Support Level
- BPMC $129.20
- PSO $14.15
- Resistance Level
- BPMC $129.65
- PSO $14.44
- Average True Range (ATR)
- BPMC 0.18
- PSO 0.14
- MACD
- BPMC -16.40
- PSO 0.03
- Stochastic Oscillator
- BPMC 0.00
- PSO 33.33
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
About PSO Pearson Plc
Pearson PLC listed in the U.K., is an educational provider. The company has been divesting non-core businesses such as the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider. While Pearson's primary activity centers on higher education, the firm also operates in providing clinical assessments, professional certification, and testing.